Neoprobe closes another $3M in funding
Neoprobe, a developer of oncology and cardiovascular surgical and diagnostic products, has completed a $3 million convertible preferred stock and warrant investment by Platinum-Montaur Life Sciences.
The Dublin, Ohio-based Neoprobe said it received the third funding of $3 million in exchange for convertible preferred stock and warrants to purchase its common stock. The third funding brings Montaur's total investment in Neoprobe to $13 million.
A Phase 3 multi-center clinical trial for Lymphoseek in patients with breast cancer or melanoma is underway and a protocol for a second Phase 3 clinical study to evaluate the efficacy of Lymphoseek as a sentinel lymph node tracing agent in patients with head and neck squamous cell carcinoma has been submitted to the FDA and the European Medicines Agency, according to the company.
The Dublin, Ohio-based Neoprobe said it received the third funding of $3 million in exchange for convertible preferred stock and warrants to purchase its common stock. The third funding brings Montaur's total investment in Neoprobe to $13 million.
A Phase 3 multi-center clinical trial for Lymphoseek in patients with breast cancer or melanoma is underway and a protocol for a second Phase 3 clinical study to evaluate the efficacy of Lymphoseek as a sentinel lymph node tracing agent in patients with head and neck squamous cell carcinoma has been submitted to the FDA and the European Medicines Agency, according to the company.